Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Monoclonal Gammopathy of Renal Significance
NCT04614558Phase 2Active, not recruiting
- Sponsor
- Columbia University
- Start
- Jun 2021
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in monoclonal gammopathy of renal significance (MGRS), sponsored by Columbia University. Started Jun 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
monoclonal gammopathy of renal significance (MGRS)
Beyond the preview
Go deeper on NCT04614558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614558.